Please elaborate on "randomly" and "anonymously".
I first approached the AAS harm reduction project using the EcstasyData.org / DDL arrangement as a model. In sum, EcstasyData (Erowids) sponsored the testing and negotiated a special discounted rate so that anyone could anonymously submit a sample for testing (as long as cash payment was included).
No accredited lab that I contacted was willing to copy this model for AAS testing/harm reduction. Among the ones willing to test AAS samples, no one would accept anonymous payment especially from dozens of different people.
The best case scenario that I may have found involves MESO sponsoring the testing and negotiating a special discounted rate for sample submissions as long as MESO (or a single entity) pays for the testing. This precludes anonymous sample submission. MESO obviously can't pay for everyone's analysis.
This would mean sample submission would be pseudonymous at best (i.e. the individuals who submit samples will be members known only by their selected usernames). The challenge would be to devise a transparent and fair method of determining who submits samples every month.
Does any member who is willing to pay x amount of dollars get to have their sample tested? Can they test 10 samples each as long as they pay? What are the problems with this? What biases will this create?
If the members who submit the sample don't have to pay anything for testing, how should they be selected? I don't think it should be a popularity contest. And I don't think it should be limited to a handful of people. Ideally, if 1,000 samples are submitted, they should be submitted by as many as 1,000 different members and certainly no less than 300-500.
But the question remains - how should they be selected? I'm leaning towards the forum points system or likes system as one criteria - only members with x number or likes or x number of points qualify for free testing. What are the problems with this? What biases wil this create?
One pragmatic issue that may influence selection is the lower costs of testing similar samples. For example, it might cost $200 per sample to test 30 samples involving 10 different steroids (3x10) but it would only cost $100 per sample to test 30 samples involving 3 different steroids (10x3). So, it would best most cost-effective (not necessarily most random) to say 'for October we are only testing methenolone enanthate, nandrolone decanoate and oxandrolone - you must have those samples to qualify for free testing'. But will this create problems or biases?
I am very open to suggestions.